Johnson & JohnsonJNJ

10-Q · 23 jul 2026 · for the period to 28 jun 2026

accession 0000200406-26-000153

the reasons · as derived · open any one to read itat latest read

every reason’s state · derivation order

01Oncology products achieved operational sales growth of 16.1% as compared to the same period a year agoContributors to the growth were: DARZALEX driven by strong share gains and market growth, CARVYKTI driven by continued share gains and site expansion, TECVAYLI driven by launch uptake and share gains from the U.S. TECVAYLI + DARZALEX FASPRO approval, TALVEY driven by share gains from expansion in the community setting, RYBREVANT/LAZCLUZE driven by launch uptake and share gainsIn the fiscal six months of 2026, the negative impact of the STELARA sales decline, due to biosimilar competition, on worldwide operational sales was approximately 5.0%Worldwide sales were $49.4 billion, a total increase of 8.2%, including an operational increase of 6.0%

pipeline depthnot in the table

holdsread 11 sep 2026

02Innovative Medicine segment income before tax as a percent of sales in the fiscal second quarter of 2026 was 38.1% versus 36.5% for the same period a year agoIn the fiscal second quarter of 2026, the Company initiated a supply chain restructuring program primarily in the Innovative Medicine segment to exit certain manufacturing locations as part of its optimization efforts to streamline operationsThe program is expected to be substantially complete by the end of 2029 with estimated costs between $650 million and $750 million

cost advantagemakes it for less than anyone else can

holdsread 11 sep 2026

03MedTech segment sales in the fiscal six months of 2026 were $17.6 billion, an increase of 6.0% as compared to the same period a year ago, with an operational increase of 4.1%Electrophysiology sales growth was driven by procedure growth, commercial execution and new product performance (VARIPULSE, TRUPULSE, NUVISION and CRYSTAL)Shockwave sales growth was driven by strong adoption of Coronary and Peripheral portfolios and new product launchesIn October 2025, the Company announced its intention to separate its Orthopaedics business

scarcity assetowns a thing that cannot be built or permitted twice

holdsread 11 sep 2026

04Cash and cash equivalents were $20.4 billion at the end of the fiscal second quarter of 2026The Company's debt position was $49.0 billion as of June 28, 2026, as compared to $50.8 billion the same period a year agoNet debt position of $28.2 billion as compared to the prior year fiscal second quarter net debt position of $31.9 billionThe Company expects to continue the practice of paying regular quarterly cash dividendsBoard of Directors declared a regular cash dividend of $1.34 per share

capital disciplinea reason to hold, not a barrier

holdsread 11 sep 2026

Anything else about this company is somebody else’s page.